Jubilant Pharmova Limited · NSE:JUBLPHARMA
Jubilant Pharmova — Jubilant Life Sciences — Q4 FY2017 Earnings Presentation
27 slides from Jubilant Pharmova's earnings presentation, May 23, 2017
Slide 1: Financial Results Quarter/Financial Year Ended March 31, 2017
Financial Results Quarter/Financial Year Ended March 31, 2017
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Conference Call Details
Conference Call Details Date : Tuesday, May 23, 2017 Time : 05:00 pm IST Primary Number: +91 22 3938 1071 3940 3977 Available in - Ahmedabad, Bengaluru, Chandigarh, Chennai, Local Access Number: Cochin, Gurgaon (NCR), Hyderabad, Kolkata, Pune, Lucknow. Accessible from all carriers. USA: 1 866 746 21
Slide 4: Q4'FY17 Results Analysis
JUBHANT LIFESCIENCES Q4’FY17 Results Analysis
Slide 5: Income Statement – Q4'FY17
Income Statement – Q4’FY17 Particulars Q4'FY16 Q4'FY17 YoY Growth (Rs Crs) (%) Total Income from Operations 1,516 1,641 8% Pharmaceuticals 785 808 3% Life Science Ingredients 691 782 13% Drug Discovery Solutions 40 51 27% Total Expenditure 1,223 1,336 9% Other Income 2 11 370% EBITDA including Other
Slide 6: Corporate Announcements
Corporate Announcements • Acquisition of Radiopharmacy business of Triad Isotopes: Jubilant Pharma Limited (JPL), Singapore, a material wholly owned subsidiary of the Company, through one of its wholly owned subsidiaries, has signed an Asset Purchase Agreement with Triad Isotopes Inc. and its parent
Slide 7: Financial Highlights – Q4'FY17
Financial Highlights – Q4’FY17 • Consolidated revenue at Rs. 1,641 Crore; up 8% YoY • Pharmaceuticals revenue at Rs. 808 Crore, contributing 49% to the revenues, up 3% YoY • Life Science Ingredients revenue at Rs. 782 Crore, contributing 48% to the revenues, up 13% YoY • Drug Discovery Solutions rev
Slide 8: Pharma Business Highlights – Q4'FY17
Pharma Business Highlights – Q4’FY17 • Revenues of Rs. 808 Crore, up 3% YoY • Specialty Pharmaceuticals (Sterile Products) revenues reported robust growth of 13% YoY; contributing 54% to segment sales • Generics revenues at Rs 370 crore, contributing 46% to segment sales • USFDA inspection at Roorke
Slide 9: Pharma Business Highlights – Q4'FY17
Pharma Business Highlights – Q4’FY17 Region-wise Revenue (Rs crs) Q4'FY16 Q3'FY17 Q4'FY17 Mix % YoY % QoQ % India 5.2% International 755 745 767 95% 2% 3% Europe & ROW North America 511 529 580 72% 14% 10% Japan 7.1% 16.0% Europe & Japan 139 138 130 16% -6% -6% ROW 106 79 57 7% -46% -27% North Ameri
Slide 10: LSI Business Highlights – Q4'FY17
LSI Business Highlights – Q4’FY17 Region-wise Revenue (Rs crs) Q4'FY16 Q3'FY17 Q4'FY17 Mix % YoY % QoQ % China and ROW International 322 273 335 43% 4% 23% 13.8% Europe, North America and Japan 227 192 227 29% 0% 19% Europe, India North 57.1% China and ROW 95 81 108 14% 14% 33% America and India 369
Slide 11: Drug Discovery Solutions Business Highlights – Q4'FY17
Drug Discovery Solutions Business Highlights – Q4’FY17 • Revenues at Rs. 51 Crore, grew 27% YoY; Contributes 3% to total revenues • EBITDA at Rs. 6 Crore, EBITDA margins at 10.9%, up from 9.2% in Q4’FY16 • Successfully achieved Toxicology milestone for US$400k for one of our out licensed proprietary
Slide 12: Annual Results Analysis
Annual Results Analysis 11 11
Slide 13: Income Statement – FY17
Income Statement – FY17 Particulars FY16 FY17 YoY Growth (Rs Crs) (%) Total Income from Operations 5,893 6,006 2% Pharmaceuticals 2,885 3,117 8% Life Science Ingredients 2,882 2,708 -6% Drug Discovery Solutions 126 182 45% Total Expenditure 4,646 4,661 0% Other Income 13 25 86% EBITDA including Othe
Slide 14: Financial Highlights – FY17
Financial Highlights – FY17 • Highest ever consolidated revenue of Rs. 6,006 Crore • Pharmaceuticals revenue at Rs. 3,117 Crore, up 8% YoY, contributing 52% to the revenues led by 11% growth in Specialty Pharmaceuticals business • LSI revenue at Rs. 2,708 Crore, contributing 45% to the revenues, dec
Slide 15: Segmental Revenue Analysis – FY17
Segmental Revenue Analysis – FY 17 • Company reports highest-ever Revenue Revenue YoY revenue of Rs. 6,006 Crore Segmental Revenue Analysis (Rs. Crs.) Mix (%) Growth % • Volume increase of 5% FY16 FY17 • Pharmaceuticals segment reports Pharmaceuticals 2,885 3,117 52% 8% revenue of Rs 3,117 Crore, 8%
Slide 16: Pharma Business Highlights – FY17
Pharma Business Highlights – FY17 • Revenues of Rs. 3,117 Crores, up 8% YoY • Specialty Pharmaceuticals (Sterile Products) revenues grew 11% YoY led by growth in all key businesses; contributed 53% to segment sales as against 52% in FY16 • Generics revenues grew 4% YoY, led by strong growth in APIs
Slide 17: Pharma Business Highlights – FY17
Pharma Business Highlights – FY17 Geo-wise Revenue (Rs crs) FY16 FY17 Mix % YoY % ROW, 9.9% International 2,741 2,923 94% 7% India, 6.2% USA & Canada 2,058 2,150 69% 4% Europe & Europe & Japan 402 466 15% 16% Japan, 14.9% ROW 281 307 10% 9% India 144 194 6% 34% USA & Canada, 69.0% Income from Operat
Slide 18: Portfolio of R&D products – Filings and Approvals
Portfolio of R&D products – Filings and Approvals Product pipeline as on March 31, 2017 Dosage (Orals) Sterile including JDI Region Total Filings Approval Pending Total Filings Approval Pending US 81 51 30 12 9 3 Canada 22 20 2 13 13 0 Europe 99 96 3 10 10 0 ROW 641 471 170 44 40 4 Total 843 638 205
Slide 19: Filings and Approvals
Filings and Approvals Dosage (Orals) Filed 81 ANDAs in the US i. 51 ANDAs have been approved and 30 ANDAs are pending approval ii. Filed 9 ANDAs in FY 17; In FY18, expect around 10 filings and 10 product launches in the US market Made 762 filings in ROW markets including Canada, Europe and Japan
Slide 20: Portfolio of Radiopharmaceuticals Sterile Products – Filings and Approvals
Portfolio of Radiopharmaceuticals Sterile Products – Filings and Approvals Orphan Drug I-131 MIBG – potential NDA filing in US i. Jubilant has received Orphan drug status with eligibility for accelerated approval, no regulatory filing fees and 7 years exclusivity ii. Indicated for paediatric Neuro
Slide 21: Regulatory Status
Regulatory Status Regulatory Cadista Roorkee CMO / Allergy CMO JDI Montreal Nanjangud • Successful audits / Agency USA India Spokane Montreal Canada India inspections by multiple regulatory agencies / customers over the last Mar 2017 Mar 2017 Nov 2016 Dec 2016 Dec 2016 Oct 2015 decade (USA) • Fast r
Slide 22: LSI Business Highlights – FY17
LSI Business Highlights – FY17 Geo-wise Revenue (Rs crs) FY16 FY17 Mix % YoY % China and International 1,347 1,146 42% -15% ROW, 12.7% Europe, North America and Japan 914 802 30% -12% Europe, North India, China and ROW 433 343 13% -21% America and 57.7% India 1,536 1,562 58% 2% Japan, 29.6% Income f
Slide 23: Drug Discovery Solutions Business Highlights – FY17
Drug Discovery Solutions Business Highlights – FY17 • Revenues at Rs. 182 Crore, grew 45% YoY; Contributes 3% to total revenues • EBITDA at Rs. 26 Crore, including out-licensing income of US$ 2 Million; Up from Rs. 2 Crore in FY 2016 • Proprietary Drug Discovery Out-licensing of family of patents
Slide 24: Expenditure Analysis – FY17
Expenditure Analysis – FY17 Expenses (Rs Crs) FY16 % of Sales FY17 % of Sales YoY Growth % Material Cost 2,117 36% 2,000 33% -6% Excise Duty on Sales 144 2% 145 2% 0% Power & Fuel Expense 367 6% 334 6% -9% Employee Benefits Expense 1,125 19% 1,231 20% 9% Other Expenses 893 15% 952 16% 7% Total Expen
Slide 25: Debt Profile
Debt Profile Particulars 31-Mar-16 31-Dec-16 31-Mar-17 Foreign Currency Loans ($ Mn) ($ Mn) ($ Mn) Standalone 55 19 19 Subsidiaries 320 403 407 Total 375 422 426 Rupee Loans (Rs. Crs) (Rs. Crs) (Rs. Crs) Standalone 1,422 1,253 1,241 Subsidiaries 626 41 82 Total 2,047 1,294 1,323 Gross Debt 4,534 4,1
Slide 26: Outlook
Outlook We expect robust growth to continue going forward, driven by our Specialty Pharma business. In FY2018, better revenues and profitability is expected, led by integration of strategic acquisition and new product launches from our strong pipeline. Revenue growth is expected to be driven by:
Slide 27: For more information
For more information For Investors: Ravi Agrawal Siddharth Rangnekar Jubilant Life Sciences Limited CDR India Ph: +91-120-436 1002 Ph: +91-22-6645 1209 E-mail: ravi_agrawal@jubl.com E-mail: siddharth@cdr-india.com For Media: Sudhakar Safaya Kanika Bansal Jubilant Life Sciences Limited Perfect Relati
Jubilant Life Sciences — Q4 FY2017 Earnings Presentation on 6ix